0701 GMT - Australia-based biotech company CSL, which collects plasma in the U.S. and manufactures many plasma-based products at plants in Europe, would likely need to raise prices by between 4% to 5.1% to offset Trump's planned tariffs on pharmaceuticals, say Jefferies analysts. While it isn't clear exactly how the Trump pharmaceutical tariffs will work, the good news for CSL is that over time it may be able to move plasma product manufacturing from high tariff locations in Europe to lower tariff areas like Australia, say David Stanton and Vanessa Thomson. This will put it in a slightly better position than its major European competitors. But in general, "plasma companies may see difficulties transferring complex, expensive operations at plants that can take years to build," they add. CSL shares ended 5% lower. (mike.cherney@wsj.com; @Mike_Cherney)

(END) Dow Jones Newswires

April 09, 2025 03:01 ET (07:01 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.